193- Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treat-
ment. A scientific statement from the American Heart Association Professional Education
Committee of the Council for high blood pressure research. Hypertension. 2008;51(6):1403–19. - Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension – its identification and epide-
miology. Nat Rev Nephrol. 2013;9(1):51–8. - James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland
DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend
RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of
high blood pressure in adults: report from the panel members appointed to the Eighth Joint
National Committee (JNC 8). JAMA. 2014;311(5):507–20. - Gijón-Conde T, Graciani A, Banegas JR. Resistant hypertension: demography and clinical
characteristics in 6,292 patients in a primary health care setting. Rev Esp Cardiol (Engl Ed).
2014;67(4):270–6. - U.S. Renal Data System Report. Available at: http://www.usrds.org/adr.aspx. Accessed 29 Feb
2016. - Pippias M, Jager KJ, Kramer A, Leivestad T, Sánchez MB, Caskey FJ, et al. The changing
trends and outcomes in renal replacement therapy: data from the ERA-EDTA registry. Nephrol
Dial Transplant. 2015;31(5):831–41. pii: gfv327 [Epub ahead of print]. - Freedman BI, Cohen AH. Hypertension-attributed nephropathy: what’s in a name? Nat Rev
Nephrol. 2016;12(1):27–36. - De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, Nappi F, Conte G,
Minutolo R. Prevalence and prognostic role of resistant hypertension in chronic kidney disease
patients. J Am Coll Cardiol. 2013;61(24):2461–7. - Ríos MT, Domínguez-Sardiña M, Ayala DE, et al. Prevalence and clinical characteristics of
isolated-office and true resistant hypertension determined by ambulatory blood pressure moni-
toring. Chronobiol Int. 2013;30(1–2):207–20. - Esteras R, Perez-Gomez MV, Rodriguez-Osorio L, Ortiz A, Fernandez-Fernandez
B. Combination use of medicines from two classes of renin-angiotensin system blocking
agents: risk of hyperkalemia, hypotension, and impaired renal function. Ther Adv Drug Saf.
2015;6(4):166–76. - Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, et al. Board of the EURECA-m
working group of ERA-EDTA. Epidemiology, contributors to, and clinical trials of mortality
risk in chronic kidney failure. Lancet. 2014;383(9931):1831–43. - SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM,
et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med.
2015;373(22):2103–16. - Rocco MV, Cheung AK. A SPRINT to the finish, or just the beginning? Implications of the
SPRINT results for nephrologists. Kidney Int. 2016;89(2):261–3. - Chertow GM, Beddhu S, Lewis JB, Toto RD, Cheung AK. Managing hypertension in patients
with CKD: a Marathon, not a SPRINT. J Am Soc Nephrol. 2016;27(1):40–3. - SPRINT Trial News Release. 2015. Available at: http://www.kdigo.org/News%20Release/
SPRINT%20Trial%20News%20Release%202015.pdf. Accessed 10 Mar 2016.
23 Instituto Nacional de Estadística. National Statistics Institute. Available at: http://www.ine.es/en/.
Accessed 29 Feb 2016.
12 Resistant Hypertension in Elderly People with Chronic Kidney Disease